Search - tctmd.com

Displaying 641 - 660 of 980

Sort: Relevancy | Date

Presentation TCT 2016

Severe AS With Simple and Complex CAD

Presenter: Jean-Claude Laborde, Wilson Y. Szeto, David Hildick-Smith

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Presenter: John A. Bittl, Daniel I. Simon, Eric Van Belle

October 30, 2016

Presentation TCT 2016

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Presenter: John A. Bittl, Daniel I. Simon, Tullio Palmerini

October 30, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation TCT 2016

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Presenter: John A. Bittl, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Presenter: John A. Bittl, Daniel I. Simon, Robert W. Yeh

October 30, 2016

Presentation TCT 2016

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Presenter: John A. Bittl, Daniel I. Simon, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Salvatore Cassese

October 30, 2016

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Laura Mauri

October 30, 2016

Presentation TCT 2016

Debate: Making the Case for Very Limited Use of Cangrelor!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Sorin J. Brener

October 30, 2016

Presentation TCT 2016

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2016

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Presenter: Deepak L. Bhatt, Christian W. Hamm

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Advertisement

Severe AS With Simple and Complex CAD

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Debate: Making the Case for Very Limited Use of Cangrelor!

Debate: Making the Case for Cangrelor Use in All PCI Patients!

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor Deep Dive: What Have We Learned From the CHAMPION Trials?

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content